Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study

Yasuda, Yuto; Hirayama, Yutaka; Uemasu, Kiyoshi; Arasawa, Soichi; Iwashima, Daisuke; Takahashi, Ken­ichi

doi:10.1016/j.resmer.2022.100903

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Triple therapy was promptly initiated in patients that required oxygenation after sotrovimab treatment. The detailed protocol used for remdesivir therapy has been described previously [ 10 ].…”

Section: Methodsmentioning

confidence: 99%

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Fujimoto

Mutsuo

Yasuda

et al. 2022

Infectious Disease Reports

View full text Add to dashboard Cite

Background: The neutralizing ability of sotrovimab and casirivimab/imdevimab against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is attenuated in the subvariant BA.5. However, the efficacy of sotrovimab in the clinical setting remains to be investigated. Methods: Patients admitted to Kishiwada City Hospital with COVID-19 delta, omicron BA.1, or BA.5 subvariants were evaluated retrospectively for serum SARS-CoV-2 S and N antibody levels using the Elecsys Anti-SARS-CoV-2 assay. Results: In patients with COVID-19 during the BA.5 wave of the COVID-19 pandemic, anti-SARS-CoV-2 S antibody titers (median [interquartile range]) increased from 2154.0 (864.0–6669.3) U/mL on day 0 to 21,371.0 (19,656.3–32,225.0) U/mL on day 3 in the group treated with sotrovimab (N = 40) and were significantly higher than in the group treated with remdesivir plus dexamethasone plus baricitinib (p < 0.001). Conclusion: Treatment with sotrovimab could prevent severe disease in high-risk patients infected with SARS-CoV-2 subvariant BA.5.

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Fujimoto

Mutsuo

Yasuda

et al. 2022

Infectious Disease Reports

View full text Add to dashboard Cite

show abstract

“…Currently, a case-by-case approach is necessary for the management of both diseases. Generally, while glucocorticoids are used in both severe COVID-19 and MIS patients, high-risk patients can receive outpatient treatment with oral antivirals such as paxlovid, molnupiravir or intravenous remdesivir early after infection, while remdesivir (with or without dexamethasone and baricitinib) can be administered in hospitalised patients or those with hypoxemia [189][190][191][192][193][194][195]. This reflects the fact that epidemiological factors allow identification of high-risk patients and the rationale for interrupting earlier stages of viral replication is better established.…”

Section: Delayed Acute Systemic Hyperinflammatory Response: Mismentioning

confidence: 99%

Severe COVID-19versusmultisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection

Fraser

Orta-Resendiz²,

Dockrell³

et al. 2023

Eur Respir Rev

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with diverse host response immunodynamics and variable inflammatory manifestations. Several immune-modulating risk factors can contribute to a more severe coronavirus disease 2019 (COVID-19) course with increased morbidity and mortality. The comparatively rare post-infectious multisystem inflammatory syndrome (MIS) can develop in formerly healthy individuals, with accelerated progression to life-threatening illness. A common trajectory of immune dysregulation forms a continuum of the COVID-19 spectrum and MIS; however, severity of COVID-19 or the development of MIS is dependent on distinct aetiological factors that produce variable host inflammatory responses to infection with different spatiotemporal manifestations, a comprehensive understanding of which is necessary to set better targeted therapeutic and preventative strategies for both.

show abstract

“…Yasuda et al [40] carried out a single centre retrospective study in Osaka, Japan, where they recruited 108 COVID-19 positive patients. Of them, 16 were treated with dexamethasone only (6 mg daily for 10 days), 2 with standard of care, 30 received the combination of 3 drugs (baricitinib 4 mg or 2 mg for 2 weeks or until no more requirement of oxygen therapy with dexamethasone and remdesivir IV with a loading dose of 200 mg and maintenance dose of 100 mg for 5 days), and 60 with only remdesivir and dexamethasone (controls).…”

Section: Covid-19 Drug Development -Recent Advances New Perspectives ...mentioning

confidence: 99%

Baricitinib in the Treatment of COVID-19

Atal¹,

Sampath²,

Banerjee³

et al. 2022

COVID-19 Drug Development - Recent Advances, New Perspectives and Applications

View full text Add to dashboard Cite

Baricitinib is a novel Janus kinase (JAK) inhibitor which has recently been included in recommendations for treatment of COVID-19. This chapter is focused on discussing the evidence available regarding the safety and efficacy of use of baricitinib alone or in combination with other therapies for treatment of patients with COVID-19. A systematic literature search was conducted for this purpose to find all clinical studies on baricitinib in treatment of COVID-19. A total of 30 studies, including both clinical trials and observational studies were identified, and they have been described briefly. Collation of the results from these observational and interventional studies shows that baricitinib either alone or in combination with other drugs, when used as an add-on to standard therapy, was found to have favorable outcomes in hospitalized patients with moderate to severe COVID-19. Furthermore, ongoing clinical trials indicate that the drug is still under evaluation across the world for its safety and efficacy in COVID-19. The recent approval of baricitinib by the US FDA for treatment of hospitalized adults with COVID-19 accurately reflects the role of the drug in COVID-19. Baricitinib improves clinical outcomes in hospitalized COVID-19 patients, and additional evidence may establish the drug as a standard treatment in such patients.

show abstract

Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study

Cited by 3 publications

References 16 publications

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants

Severe COVID-19versusmultisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection

Baricitinib in the Treatment of COVID-19

Contact Info

Product

Resources

About